SYNCELL today announced Dr. Jung-Chi Liao, its Founder, had presented SYNCELL’s Microscoop™ technology at the Cutting-edge Biotech Instrumentation Symposium hosted by Biomedical Translation Research Center and Institute for Biotechnology and Medicine Industry. Dr. Liao joined other leaders from different research fields to share their insights in applying different cutting-edge technologies in their respective basic and clinical research.

In recent years, emerging instruments have been advancing scientific frontiers and enabling novel genomics and proteomics researches that were unobtainable before. This symposium brought together users of 10X Genomics Chromium, BD Rhapsody, Nanostring GeoMX DSP, Bruker timsTOF, and SYNCELL Microscoop to discuss their applications and share thoughts on applying these new tools to broaden future research.

Dr. Pan-Chyr Yang, Academician, Academia Sinica, Chair and Professor of National Taiwan University School of Medicine, gave a welcoming remark to officially open the symposium.

The first speaker, Dr. Peter Jackson, Professor of Stanford University School of Medicine, talked about his experience in “Assaying Cell Signaling with Shotgun, Phosopho- and AP/MS Proteomics on the timsTOF Pro.”
Dr. Ruby Yun-Ju Huang, Professor, School of Medicine, National Taiwan University, presented her extensive research work on cancer microenvironment, titled “Know the Neighbor: Intra-Tumor Heterogeneity.”
Dr. Yu-Ju Chen, Research Fellow and Director of Institute of Chemistry, Academia Sinica, shared her insights on oncology proteomics and precision medicine in her talk titled “Advanced Mass Spectrometry- based Proteomics for Precision Oncology.”
Dr. Jung-Chi Liao, Research Fellow, Institute of Atomic and Molecular Sciences, Academia Sinica, described the breakthrough innovation of a new spatial biology tool, Microscoop, in his presentation titled “De novo subcellular spatial proteomics under a microscope.“
Dr. Jyh-Long Chen, Manager, BioTReC Core Facilities of Translation Medicine, talked about tools for CTC capture and single cell analysis in his presentation “Single cell analysis to dissect the cellular heterogeneity.”
Dr. Sung-Liang Yu, Professor, Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, summarized his latest single-cell based pharmacogenomics research in lung cancer in his presentation titled ”Application of Single Cell Sequencing to Lung Cancer Translation Research.”
Dr. Muh-Hwa Yang, Professor, Institute of Clinical Medicine and Vice Chancellor of National Yang-Ming University, explained genomics signatures and response variations of immunomodulatory therapeutics in his presentation titled ” Spatial evolution of the epithelial-mesenchymal signature in head and neck cancer.”
Dr. Alvon Chou, Director, Production and Process Technology Development, Mycenax Biotech Inc. described how single-cell technology was applied to drug development in his talk titled “Novel Cell Line Development with Automated Beacon Optofluidic system”
The last session was a panel discussion moderated by Dr. Yu-Chih Lin of SYNCELL Inc. with three expert panelists, Dr. Ruby Yun-Ju Huang, Dr. Yu-Ju Chen and Dr. Jung-Chi Liao. The panel discussion broadly covered many hot topics in single cell genomics and transcriptomics, low-abundant proteomics and future trends of spatial omics research and technology.

The symposium offered its more than 170 participants a rare opportunity to learn about the world’s top biomedical research tools across genomics, transcriptomics and proteomics. The meeting had successfully accomplished its goal to facilitate conversations amongst participants to stimulate new ideas for their own research.

Link: Website

About Biomedical Translation Research Center
The Biomedical Translation Research Center (BioTReC) was founded in September 2019 as a part of the National Biotechnology Research Park with the aspiration to support the development of biotechnology in Taiwan. The objectives of BioTReC align with government initiatives to accelerate bio-entrepreneurship from early discovery stages to commercialization. The center consists of three divisions, including the Translational Medicine Division, Innovation Incubation Division (BioHub Taiwan), and Smart Healthcare Division. The establishment of BioTReC helps to forge a professional and innovative ecosystem that facilitates new drug discovery, as creation of a thriving biotechnology industry will ultimately enhance human health and welfare.


About SYNCELL Inc.
SYNCELL is a development stage company with a vision to revolutionize in situ cell biology and biomedical research. The company will soon introduce its groundbreaking Microscoop™ platform, the first and only system that allows users to pick up, identify and quantify thousands of known and unknown proteins in specified cellular and subcellular locations. Microscoop™ is pairing unique imaging and illuminating capabilities with novel photolabeling chemicals to provide deep spatial proteomics insights to transform a wide range of basic biology and translational research including neuroscience, oncology, immunology, infectious disease, gene therapy, and to identify novel therapeutic targets with spatial context to accelerate drug discovery and development programs.

CONTACT:
Shuyi Liao
SYNCELL, Inc.
Phone +886-2-77505632
Info@syncell.com
Follow SYNCELL on LinkedIn at SYNCELL INC. and tag your posts with #syncell or #microscoop